First-in-Human cancer drug trial seeks to attack tumors with new method
NCT ID NCT07287995
Summary
This is the first time a new drug called ASP2998 is being tested in people. The main goal is to find a safe dose and see how well people tolerate it, either by itself or combined with standard cancer treatments. The study will enroll adults with advanced solid tumors that have spread and cannot be removed by surgery, including certain lung, bladder, stomach, and breast cancers. Researchers will also look for early signs that the drug can slow or shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC MALIGNANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
-
National Cancer Center Hospital
RECRUITINGChuo-ku, Tokyo, Japan
-
START New York Long Island
RECRUITINGNew Hyde Park, New York, 11042, United States
Conditions
Explore the condition pages connected to this study.